Two new studies have uncovered expression-defined T cell subsets that seem to coincide with better or worse outcomes in breast cancer or non-small cell lung cancer.
New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.
The partners are aiming to broaden the applicability of Genetic Technologies' BrevaGenplus breast cancer risk assessment test.
In Nature this week: Tasmanian tiger genome sequence, and more.
A genomic analysis of the Tasmanian tiger pointed to early genetic diversity declines in the species, while offering clues to convergent canid features.
A pair of researchers presents a new approach for gauging forensic Y-chromosome profile matches in PLOS Genetics.
Australian researchers call for carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy, Cosmos reports.
Using genome-wide association and targeted sequencing approaches, research teams continue to tally up genetic contributors and candidate genes in breast cancer.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.